Aiming to understand the molecular aberrations in metastatic breast cancer.
Disease site: Breast cancer
Treatment modality: Interventional screening
Status: Open to recruitment
AURORA is a large, multinational, collaborative molecular screening programme to improve understanding of metastatic breast cancer and future treatment of this disease.
In total, 1300 women and men from 14 European countries are expected to take part. In the UK, 100 patients will be recruited over a 2 year period and will be followed up for a further 10 years. Patients with either newly diagnosed local relapse or metastatic disease, or treated with no more than one line of systemic therapy in the metastatic setting, will be approached to participate.
AURORA will collect biopsy samples from both primary and metastatic tumours for molecular profiling with a panel of more than 400 cancer related genes. Blood samples collected at baseline, every 6 months and at new disease progression will also undergo molecular screening.
Information gained from the AURORA programme will help to analyse and evaluate why some tumours respond poorly to standard treatment while others respond exceptionally well, and why breast cancer metastasises.
UK Co-ordinating Investigator: Professor David Cameron, University of Edinburgh and NHS Lothian
ICR-CTSU Scientific Lead: Professor Judith Bliss
UK trial management contact: [email protected]
Sponsor and funder: Breast International Group (BIG)
Further information about AURORA is available from the UK Clinical Trials Gateway and the BIG website.
A plain English summary is available from Cancer Research UK.
Publications and presentations
There have been no presentations or publications to date.